- Home
- CHPT vs ORKA Comparison
CHPT vs ORKA Comparison
Compare CHPT & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHPT
- ORKA
- Stock Information
- Founded
- CHPT 2007
- ORKA 2004
- Country
- CHPT United States
- ORKA United States
- Employees
- CHPT N/A
- ORKA N/A
- Industry
- CHPT Industrial Specialties
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CHPT Consumer Discretionary
- ORKA Health Care
- Exchange
- CHPT Nasdaq
- ORKA Nasdaq
- Market Cap
- CHPT 468.9M
- ORKA 393.1M
- IPO Year
- CHPT N/A
- ORKA N/A
- Fundamental
- Price
- CHPT $0.62
- ORKA $9.54
- Analyst Decision
- CHPT Hold
- ORKA Strong Buy
- Analyst Count
- CHPT 10
- ORKA 7
- Target Price
- CHPT $1.58
- ORKA $39.67
- AVG Volume (30 Days)
- CHPT 7.4M
- ORKA 189.2K
- Earning Date
- CHPT 06-04-2025
- ORKA 05-19-2025
- Dividend Yield
- CHPT N/A
- ORKA N/A
- EPS Growth
- CHPT N/A
- ORKA N/A
- EPS
- CHPT N/A
- ORKA N/A
- Revenue
- CHPT $417,083,000.00
- ORKA N/A
- Revenue This Year
- CHPT $12.03
- ORKA N/A
- Revenue Next Year
- CHPT $26.85
- ORKA N/A
- P/E Ratio
- CHPT N/A
- ORKA N/A
- Revenue Growth
- CHPT N/A
- ORKA N/A
- 52 Week Low
- CHPT $0.51
- ORKA $5.49
- 52 Week High
- CHPT $2.44
- ORKA $53.88
- Technical
- Relative Strength Index (RSI)
- CHPT 49.33
- ORKA N/A
- Support Level
- CHPT $0.61
- ORKA N/A
- Resistance Level
- CHPT $0.63
- ORKA N/A
- Average True Range (ATR)
- CHPT 0.03
- ORKA 0.00
- MACD
- CHPT 0.00
- ORKA 0.00
- Stochastic Oscillator
- CHPT 31.28
- ORKA 0.00
About CHPT ChargePoint Holdings Inc.
ChargePoint designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.